SCHEMBL2837832

SCHEMBL2837832

C#CC(C)(C)OC(=O)c1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 5/20 0.50
ADRB1 P08588 5/20 0.50
ADRB3 P13945 5/20 0.50
ELANE P08246 1/20 0.50
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 1/20 0.44
GAA P10253 1/20 0.43
ALOX15 P16050 1/20 0.43
NPC1 O15118 3/20 0.42
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
ANO1 Q5XXA6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2838731 0.83 ELANE (0.50) ADRB2ADRB1ADRB3ELANEMAPT
SCHEMBL4216164 0.82 CES2 (0.52) ADRB2ADRB1ADRB3MAPTPOLB
SCHEMBL2831018 0.81 CES2 (0.49) ELANEMAPTPOLBCES2CES1
SCHEMBL11311748 0.80 POLB (0.47) ADRB2ADRB1ADRB3ELANEMAPT
Ethylene SCHEMBL28757977 0.79 CES2 (0.48) ADRB2ADRB1ADRB3MAPTPOLB
SCHEMBL9225419 0.78 ADRB2 (0.46) ADRB2ADRB1ADRB3MAPTPOLB
SCHEMBL26520508 0.77 ELANE (0.68) ADRB2ADRB1ADRB3ELANEMAPT
SCHEMBL2833508 0.75 ELANE (0.69) ADRB2ADRB1ADRB3ELANEMAPT
SCHEMBL28887005 0.74 ADRB2 (0.52) ADRB2ADRB1ADRB3MAPTPOLB
SCHEMBL2838163 0.73 ELANE (0.46) ADRB2ADRB1ADRB3ELANECES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101595082-B Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES 2013-08-21 CN disclosed
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 ADRB2 4525/4885ADRB1 4720/4885ADRB3 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.